MEI Pharma
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 102
- Market Cap
- -
- Website
- http://www.meipharma.com
- Introduction
MEI Pharma, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. Its programs include Voruciclib and ME-344. The company was founded on December 1, 2000, and is headquartered in San Diego, CA.
ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- MEI Pharma, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT05824559
- Locations
- 🇺🇸
Rutgers University, New Brunswick, New Jersey, United States
🇺🇸Mt Sinai New York, New York, New York, United States
🇺🇸Vanderbilt -Ingram Cancer Center, Nashville, Tennessee, United States
Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- MEI Pharma, Inc.
- Registration Number
- NCT05209308
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Stony Brook University, Stony Brook, New York, United States
🇺🇸OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
- Conditions
- Follicular Lymphoma (FL)Marginal Zone LymphomaNon Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2021-02-09
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- MEI Pharma, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT04745832
- Locations
- 🇺🇸
Mercy Clinic Cancer & Hematology - Chub O'Reilly Cancer Center, Springfield, Missouri, United States
🇺🇸Community Cancer Trials of Utah, Ogden, Utah, United States
🇨🇦Centre intégré universitaire de santé et de services sociaux de l'Estrie, Sherbrooke, Quebec, Canada
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)
- Conditions
- Non Hodgkin LymphomaFollicular Lymphoma (FL)Marginal Zone Lymphoma
- Interventions
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- MEI Pharma, Inc.
- Target Recruit Count
- 169
- Registration Number
- NCT03768505
- Locations
- 🇫🇷
CHD Vendee, Onco-hematologie, La Roche-Sur-Yon Cedex 9, France
🇺🇸Tower Hematology Oncology, Beverly Hills, California, United States
🇺🇸Memorial Sloan Kettering, Uniondale, New York, United States
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Acute Myeloid Leukemia (AML)Marginal Zone Lymphoma (MZL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Small Lymphocytic Lymphoma (SLL)
- Interventions
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- MEI Pharma, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT03547115
- Locations
- 🇺🇸
MD Anderson, Houston, Texas, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
- Conditions
- Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Marginal Zone B Cell LymphomaHigh Grade Non-Hodgkin's LymphomaMantle Cell Lymphoma (MCL)Follicular Lymphoma (FL)Diffuse Large B-cell Lymphoma (DLBCL)
- Interventions
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- MEI Pharma, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT02914938
- Locations
- 🇺🇸
Swedish Cancer Institute, Issaquah, Washington, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Compassionate Care, Corona, California, United States
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- MEI Pharma, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT02521389
- Locations
- 🇬🇧
Quotient Clinical, Ruddington, Nottingham, United Kingdom
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
- First Posted Date
- 2014-03-31
- Last Posted Date
- 2017-10-02
- Lead Sponsor
- MEI Pharma, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT02100007
- Locations
- 🇬🇧
The Bays St Mary's Hospital, London, England, United Kingdom
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors
- Conditions
- Solid Tumors
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2015-06-18
- Lead Sponsor
- MEI Pharma, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01544322
- Locations
- 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸University of Oklahoma, Oklahoma City, Oklahoma, United States
Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors
- First Posted Date
- 2011-07-25
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- MEI Pharma, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT01401868
- Locations
- 🇺🇸
Oklahoma University Cancer Institute, Oklahoma City, Oklahoma, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States